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homocysteine and its oxidized forms, homaystine and 
homncysteine-wlaine mixed disultido) levds were dotrr- 
mined in 170 men @wan age ? SD 50 + 7 years) with 
premature coronary artery disease diagramed at comnary 
angiography and in 255 control subjects clinically frw of 
coronary artery disease +an age 49 ? 6 years]. Patients 
with coronary artery disease had a higher bomocyst(e)hte 
level than control subjects (13.66 + 6.44 versus 10.93 + 
4.92 nmollml, p < 0.001). High density lipoprotein (HDL) 
cholesterol levels were lower (32 + 10 versus 46 2 13 mgldl, 
9 < O.WlI and Iriglycerides levels were higher (193 + 103 
versw 136 f 106 mgldl, p C O.OOll in the coronary disease 
group. Plasma total cholateml and tow density tipoproteln 
(LDL) cholerteml evels were not significaotly different 
between patients with coronary disease and control sub. 
iects. The presence ol bypertomion, rmokiig or diabetes 
mellitus did not dgrdScantly titer homocyst(e)ine levots in 
the patient or the cmttml grow. Patients who were not 
takiig P b&.adrensrgtc biockibg drug (n = 70) had P 
nonsignificantly higher homceyP(e)bte kvel than did pa- 
tients taking this class of drugs (n = LOO) (14.67 2 g.92 
versus 12.95 t 3.77 nm&d. p = 0.087). By design, mme 
of the mntmt rubjrets were taking a beta-bbxker. No 
slgnkmt corr&tions were OhsDrvDd between homwys- 
Wine and age, wum cholesterol, LDL chdatrml, HDL 
cholesterol or trielwride levels. It is concIudd that an 
cholesterol evel and the risk of developing coronary artery 
disease has been shown in several prospective epidemiologic 
studies (4.5). As plasma levels of cholesterol increase, the 
risk ofcoronary artery disease increases exponentially (6.7). 
Traditional risk factors, as determined by several pro- 
spective epidemiologic studies and the National Cholesterol 
Education Program (8). include cigarette smoking (> IO per 
day). hypertension (blood pressure alSOi mm Hg). diabe- 
tes, low density lipoprotein (LDL) cholesterol level >I60 
mgldl (4.2 mmollliter) and high density lipoprotein (HDL) 
cholesterol evel <35 mg/dl (0.9 mmollliter). The prevalence 
of these risk factors in patients with coronary artery disease 
is higher than in subjecls free of cardiovascular disease 
(9.10). However. in a significanl number of patients. no 
abnormalities in lipid metabolism or other traditional risk 
factors are identified. 
Homocystinuria is a disorder that results in marked 
elevation of homocystleline (free and bound homocysteine 
plus homocystine and homocysteine-cysteine mixed disul- 
fide) in plasma. Several inborn errors of metabolism. includ- 
ing cystathionine beta-synthase dcficicncy. ahnorm:llnic~ an 
5.methyltetrohydrofolate-dependent wlfur cooxrv~tion re- 
actions, and several condition, leading to wtarmn H,, 111 
vitamin B, deficiencies. increase homocya)mc IcvcI\. The 
clinical manifestations of homocystmuna may mclude ocular 
lectopia Icntis). skeletal loateoporosia ientral nervow rji\- 
tern (mental retardation) and va~c~~li~r (artcr~d and YFIIOU~ 
thrombosis) complications (I I). The prew~e of a mddly 
elevnted plasma level of homocyrtcine and its oridircd 
forms, bomo;ystine and bomocysteine-cy\teinc miwd d~l- 
fide, has been found in patients wth peripheral va~cul~~r 
disease (12): furthermore. the heterozygou\ wte for home. 
cystinuria was found to he frequent I” pntxnt~ wtb ccrebr,d 
arterial disease (13) based on in vitro aruy of cyrtolhionine 
beta-synthase and in vivo methionine loading. Addinonol 
studies (14-16) suggest that a mildly clcrotcd homocyaac 
level may be a risk foctor for the development of coronary 
artery disease. 
We determined plasma levels of homocyrt(ehne in men 
with angiographically documented premeturc coronary ar- 
tery disease and in a group of subjects clinically free of 
cardiovascular disease from the Framingham Heart Study. 
We analyzed the relation between lipoprotein levels and 
other risk factors and homocystceline levels and derermined 
whether hyperhomocyst(e,inemin was on independent ri,k 
factor for the development of premature coronary artery 
disease in men. On the basis of our assay we also provided 
normal ranges for homocyst(e)ine in middle-aged men. 
Methods 
Study patients. Men m = 170) ~60 yea of age (mean + 
SD 50 ? 7) underwent elective diagnostic cardiac cathctcr- 
izatiotl and coronary angiography. All had XWr diameter 
stenosis (75% cross-sectional area stenosis) of a major 
epicardial coronary artery on multiple projections. Angio- 
grams were reviewed by two cardiologists unaware of the 
patient’s inclusion in the study. Patients who su&ned an 
acute myocardial infarction. surgery or trauma in the 
6 weeks preceding their angiogram were excluded from the 
study. as were those with <SO% steno& of a coronary 
artery. Information on medication. smoking habits. hype:. 
tension and diabetes was obtained on all patients. All pa- 
tients gave written consent. The study was approved by the 
Human Investigation Review Board of the New England 
Medical Center Hospital. 
Control subjects. Men in = 255) from the Framingham 
Heart Study. aged 40 to 60 years Otwm 49 c 61. no, on a 
beta-adrenergic blocker therapy and clinically free of cerc- 
brovascular. peripheral arterial or coronary artery disease. 
formed the control group. All were cxammsd at cycle three 
of the follow-up evaluation of the Frommghom ORspring 
Heart Study (9.10). As in the patient group. mformetion on 
cardiovascular risk factors was obtained. 
Lipid and lipoprotein analysis. Blood ws collected in 
eihilenedl.lmlnetetmacctic acid IEDTA) to a final coocen- 
‘wwn of I 2 miml. Plama totol cholesterol and Iriglycer- 
adcr were meawred en~ymatically and HDL cholesterol was 
mearurcd .Ifier dextron sulfate-magnesium IMg” 1 precipit,l- 
lion. LDL choicslerol was then calculated by the method 
prcviou~ly dcrcrihad (IF19). In cases where triglyceride 
level\ ‘.va c xl00 mg/dl. lipoprotein choleuerol wr\ mea- 
wed hv ~~llr:ccnlrifuption. Our lilboratury meets !hs per- 
formance requirements of the Centers for Dicca*e Control 
hpoprotcm amdardwation progran. MultiQ!e aliquotr of 
pla\m.l acre frozen at -80°C until anzdysis. 
Homoc!rt(eline delerminatian. Determmat~on~ of plama 
homocyit(ehne ithat IS. the sum of free and bound homo- 
cy$emc. homocystine and cysteine-homocy%teine mired 
dwlfide). 51crc performed on umples froan at -RO”C. in 
both the coronary artery diceace and control groups Homo- 
cy\tlebnc Ic\els wcrc determined in coded plasma samples 
after thwing hy high pressure liquid chromatography and 
electrochemical detection. hosed on the method of Smobn 
end Schneider (20) as previously dcscribcd (I Il. with minur 
moddicst~on ,161. Results are exprewd in. nmollml of ho- 
mocycleine 
Statiatirs. Data were stored on a VAX VMS II!780 
computer IDigital Equipment) wingthe dotabase RSll (BEN 
Software). and the SAS statntical package (Stat&al Anal- 
yrn Sy\tcm,). DdTerences in variables between patienl~ 
with comnarv artery digease and control subiects before sod 
after ?..:ural~ log (inI transformation of tiglycerides and 
homocywt ;evels were compared by f tests. Nonparamet- 
ric dota were analyzed by the Mann-Whitney test. Chi- 
square dnaly\is was used to test d&rences in the frcqucncy 
of the various risk factors between patients with coronary 
artery discaxe and contml subjects. Pearson’s and Spear- 
man‘s correlation coefficients were used to test interrelation 
between the variables. Analysis of varizmce using a general 
lmcar model proccdurc was used to determine the effect of 
multiple risk factors on plasma homocystteline levels in the 
coronary xtery disease group 
RCSt!ltS 
Clinical data (Table I). The mean age of patientr was 
50 f 1 year, and that of control subjects 49 + 6 years (p = 
KOYhl. The prevalence of hypenension. smoking and diabt- 
te\ wn* higher in the coronary artery disease group than in 
the control group. The prevalence of elevated LDL choles- 
terol wa\ not significantly different between patients and 
control ahJew lower HDL cholesterol was seen more 
frequentlv in patient5 than in control subiects (data not 
,h&nl. 
Nomoryst(e)ine and lipoprotein cholesterol Iwets (Tables I 
to 4). Pla\mi levels of homocyrt(e)ine were significantly 
higher in poticnts with coronary artery disease than in 
l’abk 1. Clinical Charactenstics of Patients With Coronary Artery 
Disesse (CADI and Contml Subjects 
Control CAD 0 “Il”l 
control subjects before (13.66 t 6.44 versus 10.93 2 4.92 
nmollml, p = O.WI) and after natural log (In) transformation 
(not shown); a Mann-Whitney test of differences yielded 
similar results (Table 2). We found no significant differences 
in homocyst(e)ine levels between those aged 40 to 49 years 
and those aged 50 to 60 years in either the control or the 
coronary artery disease group (not shown). Total cholesterol 
and LDL cholesterol did not differ significantly between 
patients and control subjects, whereas triglyceride levels 
were higher(193 t 103 verw 136 ? 106 mgldl. p = 0.001) 
and HDL cholesterol was lower (32 t IO versus 46 * I3 
mgidl, p = 0.001) in patients compared with control subjects. 
There was no significant association of cholesterol, tri- 
glycerides, LDL cholesterol or HDL cholesterol in the 
prediction of homocyst(e)ine levels. No significant differ- 
ences in correlations were observed with Spearman’s cone- 
lations when compared with Pearson’s correlations (Spear- 
man3 correlation shown in Table 3). We also assessed 
whether other risk factors and beta-blocker use influenced 
homocyst(e)ine levels in the coronary artery disease group. 
Hypertensive patients did not have significantly diBerent 
homocyst(e)ine levels than normotensive patients (13.66 * 
7.67) [n = 711 versus 13.77 * 5.38 nmollml [n = 991. p = 
NS); similarly, in the control group, the presence of hyper- 
tension did not affect homocyst(e)ine levels (not shown). No 
significant differences were observed in homocyst(e)ine lev- 
els between diabetic and nondiabetic patients (14.32 ? I I. IS 
[n = 211 versus 13.58 t 5.56 nmoliml [n = 1491, p = NS). 
Beta-blocker use did not significantly alter homocyst(e)ine 
levels (14.67 ? 8.92 for those patients without the medice- 
tion [n = 701 verses 12.95 + 3.77 nmollml for those taking 
the drug [n = IOO], p = NS), although a trend suggests that 
beta-blockers may lower homocyst(e)ine levels. By design, 
no subject in the control group was taking a beta-blocker. 
The frq!xncy disrriburion of homocysr(eJine levels in 
control subjects and patients with coronary artery disease is 
shown in Figure I. Patients with coronary disease had a 
higher mean and median homocyst(e)ine level and the fre- 
quency distribution ettrve was shifted to the right compared 
with that of control subjects. Normal ranges for homo- 
cvstteline levels in control men are shown in Table 4. In the ~~ .~. 
coronary artery disease group, 75% of the patients were 
abova the 50th. 51% above the 75th. 28% above the 90th and 
% above the 95th percentile. 
Homoeyst(e)ine and other risk fnetors (Table 5). To deter- 
mine whether an elevated level of homocvst(e)ine was seen 
more frequently in patients with multiple &k factors. we 
analyzed homocyst(e)inc levels according to the presence of 
risk factors in the coronary aitery disease group. We con- 
sidered onlv modifiable risk factors. accordiw to the NP 
tioaal Cholesterol Education Prog&m (preset& of hyper- 
tension. diabetes. smoking. LDL cholesterol >]@I mgldl and 
HDL cholesterol ~35 ma/d]). Homoeyst(e)ine levels were 
then determined in patients with zero, bne, two, three, four 
or five risk factors. A I test was used to compare horn* 
cyst(e)ine levels between each group; no significant ditTer- 
ewes were observed (p = 0.012 was considered significant in 
order to compensate for multiple t tests). However, an 
analysis of variance, using a general linear model procedure 
for unbalanced data, revealed that patients with four or more 
Table 3. Correlation Cwtlicienrr’ lo Predict Homwyslte)ine Levels 
risk factors had a higher homocyat(c)inc level than rbosc 
with two risk factors (p i 0.04). 
The presence of metabohc abnommlitics, especially hpo- 
protein disorders, is frcquenr in men with premature eorv- 
nary atcry disease. However. dapitc the refinement in our 
ability to detect lipoprotein disorderr. including levels of 
apolipaprolein. nearly 25% to 35% of patients have no 
plasma lipoprotein abnormalities (?I). it is therefore bkely 
that other conditions .ay be associated with the develop- 
ment of coronary artery discarc. In this study, wc tdcnrihcd 
homocyst(e)inemia s a risk factor for the development of 
coronary artery disease indcpcndenr of hypertension. xnok- 
in& diabetes and dyslipidemias. 
Homoeystitturia. Marked elevations in homocya(eline 
can result from a variely of genetic disorders affecting 
mcthionine metabolism. Homocy,tinurka may be caused by 
deficiencies in cystathionine beta-synthase, abnormalities of 
5methyltetrahydrofolate reductase function and deficiency 
of vitamin fl,, (I I). Thrombwmbolic events result in life- 
threatening complications in patients with homocysrinuria 
(22-27). Involvement of both large and small arteries is een 
and cerebral and coronary thrombosis often lead to fatal 
ischcmic complications. Pathologic examinations have rc- 
vcaled extensive artenal abnormaliries m patients with ho- 
moeystinuria (22.26). Fibrous thickening of the corm and 
Figure 1. Yumocyrllr)mc level dirmbution in 255 eontrcl iub~ecrs 
and 170 patients with coronary anrry disc&as ICADI. 
aher .NWK~ hrarchcb rrith advanced arteriosclcrow has 
beeri doccmcntsd. 
Animnl modcts. Harker et at. (2X.2’)) ex;rmined the cffccts 
of long-rsrm homr :ys;inc mfuulen I,, male baboon, (l’,,,,,,, 
I? ~~nwpiralwl Ci mpared rilh control animal\. [hose rc- 
ccibing homocystiw infusion .hcwed patchy endo:heiiai cell 
loz\ on sxrming c cctron microscopy. The degree of endo- 
rhehal ccl1 denudation was inearly related to Qbdsma homo- 
cy\linc levels achieved in thewz animal?. Cror\ scclions of 
Ihe ~tcr~al wall revealed Fhrumuscular thickening. wirh 
smowh muxlc cell proliferation and collagen accumulation 
in the ,ubendothelial space. Platelet a~regarton was seen ai 
?ome sitcc of endothelial dcnudatlon. No changes were 
observed in in vitro indew of platelet function. Platelet 
wv~val ILU Ieduced by nearly 50% in the homocy\tinc- 
traucd ;mim&. There rewi~s from one laboratory l?Y.?Y) 
are highly ?uggcstive that homucyslinc may cxcrt a toxic 
etfccl on varcular endothelium. No mention was made of the 
role of macrophages in the oathogenrris of arterial ewns in 
that study. This work is in some respects Gmilar to studies 
(30-32) performed on nonhunan primates t.Mococo IWWI- 
Uinrr). using ii dierary h)peri.holcsterolcm~a model In these 
hypcrcholeslcrolemic monkeys. endothclial denudation oe- 
currcd edrly in the formatlor~ of the fibrous plaque: suhse- 
quent platelet aggregation 2nd increased smoolh muscle 
prolifcrarion were then obncrved. The role of macrophage~ 
in that study 130-32) appeared to hc cruciill m the Qathogen- 
ws of the fibrous plaque. 
Homocyst(e)inemia. D~wdcrs of homocyrtcine metab3- 
lism with marked elevation of plasma bomoqst(etinc levels 
arc assocnled woh severe and life-thrcatenmg vascular 
complicatiom (Ill. Our study and others 112~16,33-35) 
suggest hat milder elevation of homocystleline levels is an 
mdcpendcnt nsk factor for the develop&m of coronary and 
peripherdl artery disease. Large-scale prospective epidemi- 
ologtc ,tuJie, should he carrird ottI to confirm case conlrol 
stud& Geneix anelysts offamdies with elevated homocys- 
tteline levels may allow a bcner understanding of mecha- 
nisms involved in inrerindividual variability in plama homo- 
cystMine level,. 
Fnmrs rhor off& I nmduh~~hr of lmmocnf~r~$zr Iwrb in 
hummr uw poor/~ ur!dmrood. Family studies in moderate 
hyperhomocysl(e)inemia have not been reported. Whether 
elevated homocyst(e)ine levels are at least in pan genetically 
determined needs to be invesligated. Environmental (espe- 
cially nulritional) factors influcncin: homocystle)ine levels 
need funher research. Ii is known that f&e. pyrodoxine or 
vitamin B,? deficiency can lead 10 elevation of homo- 
cyst(eline levels (12). but the e~Tccts of subclinical deiicien- 
CM of these cofactors an homocyst(eline levels have not 
been carefully assessed. The implications of nutritional 
deficiencies (especially of vitamins B, or B,? and folatel on 
homocyst(e)ine levels may therefore represent an important 
public health issue with respect 10 the developmem of 
premature athemsclerosis. 
Treatment. The lreatmenl of moderately elevaled homo- 
cyst(e)ine is simple and inexpensive (I 136.37): although 
diets deficient in methionine are used in infants and children. 
the adult palate may be reluctant to accept such therapy. 
High doses of pyridoxal Sphosphate (vitamin 6,) have been 
shown (II) to reduce homocyst(eline levels in some caes. 
Low dose folic acid may be the treatment of choice for 
elevated homocyst(e)ine levels in the absence of vitamin B,, 
deficiency. In I3 patients. Brattstrom et al. (36) were able to 
decrease homocyslinc Icvcls by 52% with folic acid 
(5 mdday for 14 bays). Vitamin B,, (cyanocobalaminl or 8, 
lpyridoxine hydrochloride) did not have a significant effect 
on homocysteine levels. The authors (36) propose that 
excess folic acid. after conversion to 5.methyketrahydrofo- 
late. increases the rate of methyl&m of homwysleine to 
methionine. II mut be noted Ihal in their study 136). patients 
assigned 10 vitamin B,, or BA had markedly lower levels of 
homocysteine than patients assigned lo foiic acid. The role 
of vitamins B,? and B, in the treatment of elevated homo- 
cystle)ine has been ascertained (38). I[ remains 10 be deter- 
mined whether treatment of elevated plasma homocysl(e)ine 
will lead to B reduction in cardiovascular evenls a1 the 
reduction in cnolcstcroI in subjects with elevated cholesterol 
has shown (39-45). 

